Cookie Consent by Free Privacy Policy Generator Update cookies preferences

Abstracts Presentations 3 - April 26

OESO-SEMPIRE 16th World Conference | Esophagus 2024 | Strasbourg | April 23-26, 2024 | Venue: IRCAD France

<  back to Abstracts Presentations I – April 24
<  back to Abstracts Presentations II – April 25

 

Abstracts Presentations 3 - April 26


Friday, April 26, 12:30 – 1:45 pm
Rooms C.L.E.M.

  1. Prediction of additional treatment after ESD in early esophageal cancer – association with lesion size – Ji Hoon Yoon (Korea) Poster of Distinction
  2. Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling – Alexandra Lesnick (USA) Poster of Distinction
  3. Circulating tumor DNA as a marker of molecular residual disease in resected esophageal squamous cell carcinoma: A single-center, retrospective cohort study on 127 cases – Caiyan Fang (China)
  4. Cost-Effectiveness Analysis of Current Treatment Options for Eosinophilic Esophagitis – Brent Hiramoto (USA)
  5. Positive Tumor-informed Margin with TP53 Mutations Indicates Poor Surgical Outcomes in Esophageal Squamous Cell Carcinoma – Yupeng Cai (China)
  6. Border Control: Point Prevalence of Squamocolumnar Junction Abnormalities at Tandem Guideline-Based Esophagogastroduodenoscopy & Colonoscopy – Deyali Chatterjee (USA)
  7. Robotic Revisional Hiatal Hernia Repair (R-RHR): Does it Make Sense? – Christian J. Herrero Vicente (Spain)
  8. The Number of Cajal Cells in the Muscle Layer of the Esophagus in Patients with Achalasia – Elen Valitova (Russia)
  9. Redefining ypI stage of the eighth edition AJCC staging system for esophageal cancer: What’s beyond PCR? – Yan Huang (China)
  10. Risk Factors for Perforation after Endoscopic Submucosal Dissection for Esophageal Neoplasia – Kee Don Choi (Korea)
  11. Comparison of left thoracoabdominal approach with Ivor Lewis approach for treatment of esophagogastric junction cancer – Veronika Patsko (Ukraine)
  12. Clinical efficacy of taxol plus platinum (TP) chemotherapy combined with delayed administration of anti-PD-1 inhibitor in patients with locally advanced or metastatic esophageal squamous cell carcinoma – Lin Shen (China)
  13. Efficacy of esophagus protective agent based on the fixed combination of hyaluronic acid and chondroitin sulfate in the complex therapy of patients with erosive esophagitis: meta-analysis of controlled trials – Dmitrii Andreev (Russia)
  14. Exploring Peptest® Users’ Beliefs about Dietary Triggers of Gastro-Esophageal Reflux and its Associated Symptoms – Katie H.A. Boulton (UK)
  15. Genes of the HLA system in patients with different type of achalasia in Russia – Elen Valitova (Russia)
  16. Role of lower esophageal sphincter function on the symptom severity in patients with non-erosive reflux disease – Beom Jin Kim (Korea)
  17. Pathological complete response after radiochemotherapy and esophagectomy - false sense of security? – Yves Borbely (Switzerland)
  18. Multimodality treatment of the gastroesophageal junction adenocarcinoma – Valter N. Felix (Brazil)
  19. The foreign bodies in the gastrointestinal tract diagnosed by endoscopy – Jeong Seop Moon (Korea)
     

go to Abstracts Presentations I – April 24 >

go to Abstracts Presentations II – April 25 >